Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease
Identifieur interne :
000431 ( PascalFrancis/Corpus );
précédent :
000430;
suivant :
000432
Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease
Auteurs : Michael S. Okun ;
Anthony Lang ;
Joseph JankovicSource :
-
Movement disorders [ 0885-3185 ] ; 2010.
RBID : Pascal:10-0288362
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 25 |
---|
A06 | | | | @2 7 |
---|
A08 | 01 | 1 | ENG | @1 Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease |
---|
A11 | 01 | 1 | | @1 OKUN (Michael S.) |
---|
A11 | 02 | 1 | | @1 LANG (Anthony) |
---|
A11 | 03 | 1 | | @1 JANKOVIC (Joseph) |
---|
A14 | 01 | | | @1 Department of Neurology McKnight Brain Institute University of Florida @2 Gainesville, Florida @3 USA @Z 1 aut. |
---|
A14 | 02 | | | @1 Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network @2 Toronto, Ontario @3 CAN @Z 2 aut. |
---|
A14 | 03 | | | @1 Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine @2 Houston, Texas @3 USA @Z 3 aut. |
---|
A20 | | | | @1 961-962 |
---|
A21 | | | | @1 2010 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000193040220300 |
---|
A44 | | | | @0 0000 @1 © 2010 INIST-CNRS. All rights reserved. |
---|
A45 | | | | @0 2 ref. |
---|
A47 | 01 | 1 | | @0 10-0288362 |
---|
A60 | | | | @1 P |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B17 |
---|
C02 | 02 | X | | @0 002B17G |
---|
C03 | 01 | X | FRE | @0 Maladie de Parkinson @2 NM @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinson disease @2 NM @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson enfermedad @2 NM @5 01 |
---|
C03 | 02 | X | FRE | @0 Pathologie du système nerveux @5 02 |
---|
C03 | 02 | X | ENG | @0 Nervous system diseases @5 02 |
---|
C03 | 02 | X | SPA | @0 Sistema nervioso patología @5 02 |
---|
C03 | 03 | X | FRE | @0 Homme @5 09 |
---|
C03 | 03 | X | ENG | @0 Human @5 09 |
---|
C03 | 03 | X | SPA | @0 Hombre @5 09 |
---|
C03 | 04 | X | FRE | @0 Glutathion @5 10 |
---|
C03 | 04 | X | ENG | @0 Glutathione @5 10 |
---|
C03 | 04 | X | SPA | @0 Glutatión @5 10 |
---|
C07 | 01 | X | FRE | @0 Pathologie de l'encéphale @5 37 |
---|
C07 | 01 | X | ENG | @0 Cerebral disorder @5 37 |
---|
C07 | 01 | X | SPA | @0 Encéfalo patología @5 37 |
---|
C07 | 02 | X | FRE | @0 Syndrome extrapyramidal @5 38 |
---|
C07 | 02 | X | ENG | @0 Extrapyramidal syndrome @5 38 |
---|
C07 | 02 | X | SPA | @0 Extrapiramidal síndrome @5 38 |
---|
C07 | 03 | X | FRE | @0 Maladie dégénérative @5 39 |
---|
C07 | 03 | X | ENG | @0 Degenerative disease @5 39 |
---|
C07 | 03 | X | SPA | @0 Enfermedad degenerativa @5 39 |
---|
C07 | 04 | X | FRE | @0 Pathologie du système nerveux central @5 40 |
---|
C07 | 04 | X | ENG | @0 Central nervous system disease @5 40 |
---|
C07 | 04 | X | SPA | @0 Sistema nervosio central patología @5 40 |
---|
N21 | | | | @1 186 |
---|
N44 | 01 | | | @1 OTO |
---|
N82 | | | | @1 OTO |
---|
|
Format Inist (serveur)
NO : | PASCAL 10-0288362 INIST |
ET : | Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease |
AU : | OKUN (Michael S.); LANG (Anthony); JANKOVIC (Joseph) |
AF : | Department of Neurology McKnight Brain Institute University of Florida/Gainesville, Florida/Etats-Unis (1 aut.); Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network/Toronto, Ontario/Canada (2 aut.); Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine/Houston, Texas/Etats-Unis (3 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 961-962; Bibl. 2 ref. |
LA : | Anglais |
CC : | 002B17; 002B17G |
FD : | Maladie de Parkinson; Pathologie du système nerveux; Homme; Glutathion |
FG : | Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central |
ED : | Parkinson disease; Nervous system diseases; Human; Glutathione |
EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
SD : | Parkinson enfermedad; Sistema nervioso patología; Hombre; Glutatión |
LO : | INIST-20953.354000193040220300 |
ID : | 10-0288362 |
Links to Exploration step
Pascal:10-0288362
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease</title>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology McKnight Brain Institute University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name>
<affiliation><inist:fA14 i1="02"><s1>Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288362</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288362 INIST</idno>
<idno type="RBID">Pascal:10-0288362</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000431</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease</title>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology McKnight Brain Institute University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name>
<affiliation><inist:fA14 i1="02"><s1>Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glutathione</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Homme</term>
<term>Glutathion</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OKUN (Michael S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LANG (Anthony)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology McKnight Brain Institute University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>961-962</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193040220300</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>2 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0288362</s0>
</fA47>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Glutathion</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Glutathione</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Glutatión</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>186</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0288362 INIST</NO>
<ET>Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease</ET>
<AU>OKUN (Michael S.); LANG (Anthony); JANKOVIC (Joseph)</AU>
<AF>Department of Neurology McKnight Brain Institute University of Florida/Gainesville, Florida/Etats-Unis (1 aut.); Toronto Western Hospital Movement Disorders Center University of Toronto and University Health Network/Toronto, Ontario/Canada (2 aut.); Department of Neurology Parkinson's Disease Center and Movement Disorders Clinic Baylor College of Medicine/Houston, Texas/Etats-Unis (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 7; Pp. 961-962; Bibl. 2 ref.</SO>
<LA>Anglais</LA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du système nerveux; Homme; Glutathion</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Human; Glutathione</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Hombre; Glutatión</SD>
<LO>INIST-20953.354000193040220300</LO>
<ID>10-0288362</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000431 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000431 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:10-0288362
|texte= Reply: Based on the Available Randomized Trial Patients Should Say No to Glutathione for Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022 | |